Scientific Presentations Summer 2009 - Dana-Farber/Harvard ...

More documents

Recommendations

Info

Early Detection of Morphological Changes After Massive Small Bowel Resection in Rats Winta Haile Mentor: Stanley Ashley, MD Scientific Advisor: Anita Balakrishnan, MD Brigham and Women’s Hospital Although small bowel resection incites adaptive morphological changes in remnant intestine, such changes have only been identified a week beyond resection. We aimed to determine whether these changes would occur at two days post-resection. Sprague Dawley rats were subjected to either 80% resection (n=4)or transection and reanastomosis (n=4) of the small bowel. Two days later, rats were sacrificed and sections of remaining jejunum harvested, fixed in formalin and embedded in paraffin. 7um thick sections were stained with haematoxylin and eosin and used for measurement of villous height and width, crypt depth, enterocytes per crypt, enterocytes per villus, and smooth muscle thickness. I anticipate changes in morphology following resection in response to small bowel length, such as increases in villous height, crypt depth, number of enterocytes per crypt and villus, and smooth muscle thickness. If we find reproducible morphological changes in response to resection, we can use this model to identify potential specific genetic pathways regulating the adaptive response. Identifying early morphological changes and the regulating factors will allow improved treatments for patients with insufficient adaptation in short bowel syndrome.
Patient Acceptability of the Electronic Self Report Assessment Cancer Program (ESRA-C) Version 2 to Enhance Communication Between Patients and Clinicians Tanya Harrison Mentor: Donna Berry, PhD, RN, AOCN, FAAN Scientific Advisor: Barbara Halpenny, MA Dana-Farber Cancer Institute Assessing cancer symptoms and quality of life issues is essential for excellent clinical care in cancer patients. The Electronic Self Report Assessment-Cancer program (ESRA-C) version 1 was demonstrated to be an efficacious and acceptable method to cancer patients for reporting symptom and quality of life information to clinicians. ESRA-C version 2 is a further developed program that contains additional symptom questionnaires and has been used in a multi-site sample in a randomized clinical trial at two comprehensive cancer centers. The objective of this analysis is to determine if ESRA-C version 2 is as equally acceptable to patients as version 1 and whether acceptability differed in various demographics. We evaluated the average score of the five acceptability questions with response options ranging from one (not at all acceptable) to six (very much acceptable) among patients that have completed ESRA-C version 2. We also assessed demographics such as age, gender, and computer literacy. Results showed that 40% of the sample (n=65) are female, 40% are age 60 or older, and only 74% of the participants use a computer often or very often. There were no differences in acceptability of the program between men and women, patients under or over 60 years old, and frequent or non-frequent computer users. Although specific measures of acceptability varied between the two groups, the average acceptability score was lower in version 2. We conclude that ESRA-C version 2 is not as equally acceptable to patients as version 1 due to the amount of time it takes for the participants to complete the report.
Page 1 and 2: Dana-Farber/Harvard Cancer Center C
Page 3: CURE Scientific Presentations Dana
Page 6 and 7: Production of ß 2 M and HLA-A2 for
Page 8 and 9: The extracellular matrix influences
Page 10 and 11: Identification of novel genes that
Page 12 and 13: Co-crystallization of PIP2 and the
Page 14 and 15: Conjugating Aptamers to Nanorods Al
Page 16 and 17: The Growth of Malignant Plasma Cell
Page 18 and 19: High level baseline in language fmr
Page 22 and 23: Investigating the role of Esrrb and
Page 24 and 25: Exploring the Effects of Estrogen o
Page 26 and 27: Untitled Michel Moravia Mentor: Mic
Page 28 and 29: Massively Parallel Amplification of
Page 30 and 31: The Role of TPBG in Melanoma Metast
Page 32 and 33: Role of selectins in the pathogenes
Page 34 and 35: Tumor-derived Neuropilin-2 acts as
Page 36 and 37: Genetic Characterization of a New L
Page 38 and 39: Optimizing HA Immunopurification St
Page 40 and 41: CDK8 overexpression as a possible r
Page 42 and 43: Nerve Regeneration II Further Studi
Page 47 and 48: Dana-Farber/Harvard Cancer Center

Scientific Presentations Summer 2009 - Dana-Farber/Harvard ...

Create successful ePaper yourself

Delete template?

Save as template?